Menu

Overview

Performance

Holdings

Listings

Fund Documents

Overview

Investment Strategy:

KURE seeks to measure the performance of MSCI China All Shares Health Care 10/40 Index. The Index is a free float adjusted market capitalization weighted index designed to track the equity market performance of Chinese companies engaged in the health care sector. The securities in the Index include all types of publicly issued shares of Chinese issuers, which are listed in Mainland China, Hong Kong and the United States. Issuers eligible for inclusion must be classified under the Global Industry Classification Standard (GICS) as engaged in the healthcare sector. The issuers included in the Underlying Index may include small-cap, mid-cap and large-cap companies.

China Health Care Sector Highlights:

  • China is one of the fastest growing major healthcare markets in the world with a ten-year compound annual growth rate of 13%, compared to just 3% in the United States and 2% in Japan1.
  • China is the second largest healthcare market globally with total healthcare expenditures reaching $1.02 trillion in 2019, an increase of roughly 87% over the last 5 years2.
  • There is still opportunity for considerable growth in China’s healthcare market with per capita health spending at just $441, compared to an average of over $5,400 for the world’s top eight healthcare markets3.
  • China’s aging population, rising incomes and increasing urbanization may provide a sustained catalyst for growth in China’s healthcare sector.

KURE features:

  • Exposure to Chinese companies listed in the Mainland, Hong Kong and United States that are involved in the healthcare industry. Specifically: patent and generic pharmaceuticals, hospital administration, biotechnology, medical equipment production, healthcare IT, and traditional Chinese medicine.
  • Exposure to companies that benefit from China’s growing middle class and aging population.
  • Access to leading Chinese pharmaceutical companies which have been recipients of favorable policy and market conditions for research and development and the invention of new medicines and devices.

1.) Major healthcare markets defined as top five global markets by the World Health Organization. Data from the World Health Organization as of 31/Dec/2017, last updated on 7/Apr/2020. Retrieved 31/Dec/2020.

2.) Statista, Health expenditure in China 2000-2019”, Published by Lai Lin Thomala, Dec 17, 2020, Retrieved 31/Dec/2020.

3.) Data from the World Health Organization, last updated on 7/Apr/2020. Retrieved 31/Dec/2020.

Fund Details

Data as of 20/Mar/2023
Ticker KURE
Primary SEDOL BMZ4LD0
Primary ISIN IE00BL6K0S82
Net Assets $3,573,340
Total Annual Fund Operating Expense 0.65%
Inception Date 14/Jan/2021
Distribution Frequency Accumulating

Daily Performance

Data for USD share class as of 20/Mar/2023
Daily Net Asset Value (NAV)
NAV $14.29
NAV Daily Change -2.52%

Performance History

Cumulative %
Data for USD share class as of: 28/Feb/2023
Fund NAV Index
1 Month -7.36% -7.15%
3 Month 5.11% 5.90%
6 Month 4.24% 4.93%
Since Inception -39.08% -37.33%
Avg Annualized %
Data for USD share class as of month end: 28/Feb/2023
Fund NAV Index
1 Year -12.92% -12.35%
Since Inception -20.79% -19.73%
Avg Annualized %
Data for USD share class as of quarter end: 31/Dec/2022
Fund NAV Index
1 Year -25.62% -25.22%
Since Inception -22.64% -21.71%

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted.

Topics:

Top 10 Holdings

Data as of 21/Mar/2023 Full Holdings .CSV
Rank Name % of Net Assets Ticker Identifier Shares Held Market Value($)
1 WUXI BIOLOGICS CAYMAN INC 8.80% 2269 KYG970081173 52,000 325,723
2 SHENZHEN MINDR-A 6.35% 300760 CNE100003G67 5,300 235,193
3 JIANGSU HENGRU-A 4.55% 600276 CNE0000014W7 27,880 168,470
4 BEIGENE LTD 4.35% 6160 KYG1146Y1017 9,200 160,866
5 AIER EYE HSPTL-A 3.82% 300015 CNE100000GR6 31,598 141,459
6 CSPC PHARMACEUTI 3.70% 1093 HK1093012172 132,000 137,105
7 WUXI APPTEC CO LTD-A 3.57% 603259 CNE1000031K4 11,320 131,972
8 ZHANGZHOU PIEN-A 2.87% 600436 CNE000001F21 2,600 106,276
9 CHONGQING ZHIF-A 2.52% 300122 CNE100000V20 7,100 93,345
10 SINO BIOPHARMACEUTICAL 2.31% 1177 KYG8167W1380 153,000 85,406

Holdings are subject to change.

Listings

Data as of 20/Mar/2023
Exchange Ticker Currency Listing Date SEDOL ISIN
London Stock Exchange KURE LN USD 14/Jan/2021 BMZ4LD0 IE00BL6K0S82
Borsa Italiana KURE IM EUR 13/Oct/2022 — IE00BL6K0S82

Each share class is offered in the base currency noted above. To the extent the fund holds exposure to any positions in a currency different to the base currency, that position is unhedged.

Fund Documents

©2023 Krane Funds Advisors, LLC
280 Park Avenue, 32nd Floor, New York, NY 10017

Investing involves risk, including possible loss of principal. There can be no assurance that a Fund will achieve its stated objectives. The Funds are subject to political, social or economic instability within China which may cause decline in value. Fluctuations in currency of foreign countries may have an adverse effect to domestic currency values. Emerging markets involve heightened risk related to the same factors as well as increase volatility and lower trading volume.

Narrowly focused investments typically exhibit higher volatility. Internet companies are subject to rapid changes in technology, worldwide competition, rapid obsolescence of products and services, loss of patent protections, evolving industry standards and frequent new product productions. Such changes may have an adverse impact on performance.

This material is for information only and does not constitute an offer or recommendation to buy or sell any investment, or subscribe to any investment management or advisory service. It is not, under any circumstances, intended for distribution to the general public. You are accessing information which constitutes a financial promotion under section 21 of the Financial Services and Markets Act 2000 ("FSMA"). In relation to the United Kingdom, this information is only directed at, and may only be distributed to, persons who are “Investment Professionals” (being persons having professional experience in matters relating to investments) within the meaning of article 19(5) of the FSMA (Financial Promotion) Order 2005 (the “Financial Promotion Order ”), persons to whom any of paragraphs (2)(a) to (d) of article 49 (high net worth companies, unincorporated associations etc.) of the financial promotion order apply, or persons to whom distribution may otherwise lawfully be made.

Any investment, and investment activity or controlled activity, to which this information relates is available only to such persons and will be engaged in only with such persons. Persons that do not have professional experience should not rely or act upon this information unless they are persons to whom any of paragraphs (2)(a) to (d) of article 49 apply to whom distribution of this information may otherwise lawfully be made.

The views and opinions expressed in this material are those of the authors Krane Fund Advisors. These opinions have been given in good faith but are subject to change without notice. It is the responsibility of the investor to evaluate the accuracy, completeness and usefulness of any opinions, advice, services, or other information provided.

This material may not be suitable for all investors. Any performance quoted represents past performance and is no guarantee of future results. Past performance is not indicative or a guarantee of future performance. Carefully consider the Funds' investment objectives, risk factors, charges and expenses before investing. This and additional information, including historical and the most recent month-end performance, can be found in the Fund Literature (Prospectus, Supplement, KIID), which may be obtained at our website www.kraneshares.eu or at the website of our management company www.waystone.com. KIID documents are available in the language of any Member State where such fund is distributed.

Krane Funds Advisors, LLC is appointed to act as investment manager in accordance with the requirements of the Central Bank. Waystone Management Company (IE) Limited is appointed to provide management services to the ICAV in accordance with the requirements of the Central Bank. The Management Company may decide to terminate the arrangements made for the marketing of the Fund in accordance with Article 93a of Directive 2009/65/EC.

Privacy Policy

Summary of Investor Rights

You are now leaving KraneShares.eu

Hyperlinks on this website are provided as a convenience and we disclaim any responsibility for information, services or products found on the websites linked hereto.

Click here to continue

Welcome to Kraneshares

Please select your region and investor type to enter the site:

United Kingdom
Finland
Germany
Ireland
Italy
Netherlands
Portugal
Spain
Sweden
Switzerland
United Kingdom

Individual Investor

I manage my own money

Financial Professional

I consult with, or represent, organisations, beneficiaries or institutions

To start your visit, you have read and accepted our terms and conditions (“Terms”): 

Our corporate website www.KraneShares.eu (referred to as the “website”) is owned by KraneShares. By accessing and using the website you agree to be bound by all terms and conditions which are set out on the website from time to time, which govern such access and use (the “Terms and Conditions”).

Nothing on this website is advice on the merits of any product or investment, nothing constitutes investment, legal, tax or any other advice nor is it to be relied on in making an investment decision. Prospective investors should obtain independent investment advice and inform themselves as to applicable legal requirements, exchange control regulations and taxes in their jurisdiction. This website is for information only. It is not an invitation to buy or sell an investment. It does not provide investment, tax or legal advice or recommendations and is not intended to be independent investment research.   

Distribution of Information: 

The distribution of the information and material on this website may be restricted by law in certain countries. None of the information is directed at, or is intended for distribution to, or use by, any person or entity in any jurisdiction (by virtue of nationality, place of residence, domicile or registered office) where publication, distribution or use of such information would be contrary to local law or regulation, or would subject KraneShares or any funds it markets to any registration or licensing requirements in such jurisdiction. 

You must inform yourself about, and observe any such restrictions in your jurisdiction and by accessing the website applicable to you. The information on this website is not for distribution and does not constitute an offer to sell or the solicitation of any offer to buy any securities in the United States to or for the benefit of any United States person (being residents of the United States or partnerships or corporations organised under the laws thereof). The funds on this Website have not been registered in the United States under the Investment Company Act of 1940 and interests therein are not registered in the United States under the Securities Act of 1933. 

Liability & Indemnity: 

KraneShares is not responsible for the accuracy, completeness or reliability of any data, statistics, commentary or content in any media format on www.KraneShares.eu. KraneShares will not be held responsible for any financial losses incurred as a result of believing the content of materials on this website; or materials and content linked to from this website. Investors should read the Prospectus, KID or KIID as applicable and take independent legal, tax and investment advice before investing in any fund.

If you do not comply with the Terms and Conditions of this website, you may not hold KraneShares responsible for any liabilities, losses or damages derived from use of this website.

Specific risk warnings are set out in the prospectus and if applicable the supplement for the relevant product.

Website User Categorisation:

ONLY APPLICABLE IF YOU ARE AN INSTITUTIONAL INVESTOR 

By entering the institutional investor section of the website, you affirm either that you are a Per Se Professional Client, or that you wish to be treated as an Elective Professional Client, both as defined under the Markets in Financial Instruments Directive, or a Qualified Investor as defined under the Prospectus Regulation, Regulation (EU) 2017/1129 or an equivalent in a jurisdiction outside the EEA (e.g. the equivalent term In Switzerland, the equivalent term is Professional Client or Institutional Client according to the Federal Act on Financial Services) (“Institutional Investor”) and you have read, understood and accepted the Terms and Conditions. The institutional investor section of the website is not intended for retail or private investors. 

In accessing the website as an Institutional Investor you will be undertaking, warranting and representing to KraneShares that you are an Institutional Investor. Please note that KraneShares will be acting in reliance upon your undertaking, warranty and representation and you shall indemnify us and hold us harmless against all claims liabilities, losses, damages, costs and expenses incurred or suffered by us by reason of any breach of such undertaking, warranty and representation. 

As a matter of general policy, KraneShares will not conduct regulated investment activities with any person as a result of their receiving information from the website, unless agreed otherwise with an Institutional Investor. 

Disclaimer: 

  • This material may not be suitable for all investors. Any performance quoted represents past performance and is no guarantee of future results. Past performance is not indicative or a guarantee of future performance. 
  • This information should not be relied upon as research, investment advice, or a recommendation regarding any products, strategies, or any security in particular. This material is strictly for illustrative, educational, or informational purposes and is subject to change. Certain content represents an assessment of the market environment at a specific time and is not intended to be a forecast of future events or a guarantee of future results; material is as of the dates noted and is subject to change without notice.  
  • The price, value, yield and liquidity of any security or fund can go up and down and may be impacted by Currency Risks, Liquidity Risks, Political Risks, Credit Risks, Tax Risks and Market Risks. Professional advice should be taken before investing in any of our funds (or in any security).
  • Carefully consider the Funds' investment objectives, risk factors, charges and expenses before investing. 
  • KraneShares may change the Terms and Conditions of use for www.KraneShares.eu at any time, for any reason, without notice. 

To find out more about how personal data is collected on our websites, please see our Privacy Policy.

Edit your location and investor type below

United Kingdom
Finland
Germany
Ireland
Italy
Netherlands
Portugal
Spain
Sweden
Switzerland
United Kingdom

Individual Investor

I manage my own money

Financial Professional

I consult with, or represent, organisations, beneficiaries or institutions

Invest in KURELN Through Your Broker

You are now leaving KraneShares.com. Hyperlinks on these websites are provided as a convenience and we disclaim any responsibility for information, services or products found on the websites linked hereto.